Jefferies Gives a Buy Rating to INC Research Holdings

By Carrie Williams

In a report released today, David Windley from Jefferies reiterated a Buy rating on INC Research Holdings (NASDAQ: INCR), with a price target of $51. The company’s shares opened today at $43.95.

According to, Windley is a top 100 analyst with an average return of 15.8% and a 74.8% success rate. Windley covers the Healthcare sector, focusing on stocks such as Quintiles Transnational, WellCare Health Plans, and PRA Health Sciences.

INC Research Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $51.25.

Based on INC Research Holdings’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $406 million and quarterly net profit of $37.49 million. In comparison, last year the company earned revenue of $413 million and had a net profit of $17.41 million.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC.